Fuji Pharma Co (TSE:4554) Cyclically Adjusted Revenue per Share: 円1,622.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4554 Fuji Pharma Co Ltd TSE:4554
89 GF Score
Price 円1,896.00
GF Value 円1,858.85
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Fuji Pharma Co Cyclically Adjusted Revenue per Share?

Fuji Pharma Co TSE:4554 -0.05% 89 Cyclically Adjusted Revenue per Share is 円1,622.07 as of Mar. 2026. GuruFocus rates TSE:4554 with a GF Score™ of 89/100 and a GF Value™ of 円1,858.85 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fuji Pharma Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円557.105. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,622.07 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fuji Pharma Co's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fuji Pharma Co was 9.10% per year. The lowest was 3.90% per year. And the median was 7.30% per year.

As of today (2026-07-31), Fuji Pharma Co's current stock price is 円1896.00. Fuji Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円1,622.07. Fuji Pharma Co's Cyclically Adjusted PS Ratio of today is 1.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fuji Pharma Co was 2.02. The lowest was 0.80. And the median was 1.09.


Fuji Pharma Co  (TSE:4554) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Fuji Pharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1896.00/1622.07
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fuji Pharma Co was 2.02. The lowest was 0.80. And the median was 1.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fuji Pharma Co Cyclically Adjusted Revenue per Share Related Terms


Fuji Pharma Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fuji Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuji Pharma Co Cyclically Adjusted Revenue per Share Chart

Fuji Pharma Co Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,101.24 1,199.26 1,305.40 1,419.81 1,556.38

Fuji Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,491.53 1,524.95 1,556.38 1,601.05 1,622.07

TSE:4554 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fuji Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuji Pharma Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuji Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fuji Pharma Co's Cyclically Adjusted PS Ratio falls into.


TSE:4554
89GF Score
Fuji Pharma Co Ltd TSE:4554
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fuji Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fuji Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=557.105/112.7000*112.7000
=557.105

Current CPI (Mar. 2026) = 112.7000.

Fuji Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 273.815 98.100 314.566
201609 307.510 98.000 353.637
201612 298.529 98.400 341.913
201703 280.406 98.100 322.138
201706 290.411 98.500 332.277
201709 313.087 98.800 357.135
201712 332.654 99.400 377.164
201803 267.335 99.200 303.716
201806 331.150 99.200 376.216
201809 335.439 99.900 378.418
201812 343.504 99.700 388.294
201903 274.088 99.700 309.827
201906 284.295 99.800 321.043
201909 287.378 100.100 323.551
201912 287.870 100.500 322.815
202003 254.726 100.300 286.218
202006 256.580 99.900 289.455
202009 285.412 99.900 321.981
202012 298.309 99.300 338.564
202103 287.526 99.900 324.366
202106 338.174 99.500 383.037
202109 349.652 100.100 393.664
202112 389.077 100.100 438.052
202203 340.685 101.100 379.774
202206 359.924 101.800 398.462
202209 368.605 103.100 402.927
202212 411.443 104.100 445.433
202303 379.747 104.400 409.938
202306 422.064 105.200 452.154
202309 469.327 106.200 498.052
202312 442.131 106.800 466.556
202403 437.726 107.200 460.184
202406 484.059 108.200 504.191
202409 534.038 108.900 552.673
202412 534.561 110.700 544.219
202503 455.292 111.100 461.849
202506 527.505 111.700 532.228
202509 603.327 112.000 607.098
202512 651.570 113.000 649.840
202603 557.105 112.700 557.105

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,622.07 mean?
Fuji Pharma Co (TSE:4554) has a Cyclically Adjusted Revenue per Share of 円1,622.07 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fuji Pharma Co and its competitors.
Is Fuji Pharma Co's Cyclically Adjusted Revenue per Share too high?
Fuji Pharma Co's current Cyclically Adjusted Revenue per Share is 円1,622.07. Overall, Fuji Pharma Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fuji Pharma Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Fuji Pharma Co's Cyclically Adjusted Revenue per Share of 円1,622.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fuji Pharma Co and its competitors. Fuji Pharma Co's current Cyclically Adjusted Revenue per Share is 円1,622.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuji Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Fuji Pharma Co (TSE:4554) is currently considered Fairly Valued. The stock's GF Value™ is 円1,858.85, compared to a current price of 円1,896.00 — trading 2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,622.07. Fuji Pharma Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fuji Pharma Co (TSE:4554), the current Cyclically Adjusted Revenue per Share is 円1,622.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fuji Pharma Co (TSE:4554) Overvalued in 2026?

Based on GuruFocus' analysis, Fuji Pharma Co stock appears to be overvalued. The current stock price of 円1,896.00 is trading 2% above its estimated GF Value™ of 円1,858.85. GuruFocus considers Fuji Pharma Co to be Fairly Valued.

Key valuation signals for TSE:4554:

  • Cyclically Adjusted Revenue per Share: 円1,622.07
  • GF Value™: 円1,858.85 vs. price of 円1,896.00 (2% above fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the TSE:4554 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fuji Pharma Co Business Description

Address 5-7 Sanban-cho, Chiyoda-ku, Tokyo, JPN, 102-0075
Fuji Pharma Co Ltd is involved in the development, manufacture, and marketing of pharmaceutical products, such as injection agents, internal drugs, drugs for external use, and diagnostic products. The group consists of a single segment, the pharmaceutical business.
89GF Score

Get the complete analysis for TSE:4554

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,896.00
Price
円1,858.85
GF Value